Dr. Reddy’s Laboratories Ltd. announced that it has launched Cefixime for Oral Suspension, USP 100 mg/5mL and 200 mg/5mL, a therapeutic equivalent generic version of Suprax® (cefixime) for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).
The Suprax® brand and generic had U.S. sales of approximately $50.5 million MAT for the most recent twelve months ending in June 2017 according to IMS Health.
Dr. Reddy’s Cefixime for Oral Suspension, USP is available in strengths of 100 mg/5mL and 200 mg/5mL after reconstitution. The 100 mg/5 mL strength is available in 50 mL bottles. The 200 mg/5 mL strength is available in 75 mL and 50 mL bottles.
Suprax® is a registered trademark of Astellas Pharma Inc.
*IMS National Sales Perspective: Retail and Non-Retail MAT June 2017
